75541-83-2 Usage
Description
EXO1 is a cell-permeable, reversible inhibitor of exocytosis with an IC50 value of 20 μM. It plays a crucial role in interfering with protein trafficking and secretion by disrupting the interaction between the GTPase activator ADP-ribosylation factor (ARF1) and Golgi membranes. This leads to the collapse of the Golgi apparatus, making EXO1 a significant compound in cellular processes.
Uses
Used in Cellular Processes Research:
EXO1 is used as a research tool for studying cellular processes, particularly those involving protein trafficking and secretion. Its ability to dissociate ARF1 from Golgi membranes allows scientists to investigate the effects of this interaction on cellular functions.
Used in Anti-Inflammatory Applications:
EXO1 has demonstrated potential anti-inflammatory activity, making it a valuable compound for exploring its use in treating inflammation-related conditions.
Used in Membrane Trafficking Studies:
EXO1 has been utilized in the study of coat protein 1 (COPI)-mediated membrane trafficking, as it serves as a Golgi inhibitor. This application helps researchers understand the role of Golgi apparatus in cellular transport mechanisms.
Used in Retrotransposition Research:
EXO1 has been employed in the investigation of long interspersed nuclear element-1 (L1) retrotransposition. As a Golgi inhibitor, it aids in understanding the impact of Golgi apparatus disruption on this process.
Used in Buffer Composition:
EXO1 has been used as a component of the BRB80 buffer, which is essential for studying various cellular processes and interactions. Its presence in the buffer allows for a more comprehensive understanding of the cellular environment and its influence on these processes.
Biochem/physiol Actions
Exo 1 is a cell-permeable methylanthranilate analog that promotes the release of adenosine diphosphate (ADP)-ribosylation factor (ARF) 1 from Golgi membranes. It also inhibits the membrane trafficking between the endoplasmic reticulum (ER) and the Golgi bodies.
Check Digit Verification of cas no
The CAS Registry Mumber 75541-83-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,5,5,4 and 1 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 75541-83:
(7*7)+(6*5)+(5*5)+(4*4)+(3*1)+(2*8)+(1*3)=142
142 % 10 = 2
So 75541-83-2 is a valid CAS Registry Number.
InChI:InChI=1/C15H12FNO3/c1-20-15(19)12-4-2-3-5-13(12)17-14(18)10-6-8-11(16)9-7-10/h2-9H,1H3,(H,17,18)
75541-83-2Relevant articles and documents
Novel O-acylated (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-one oximes targeting HSP90-HER2 axis in breast cancer cells
Piven, Yuri A.,Yastrebova, Margarita A.,Khamidullina, Alvina I.,Scherbakov, Alexander M.,Tatarskiy, Victor V.,Rusanova, Julia A.,Baranovsky, Alexander V.,Zinovich, Veronica G.,Khlebnicova, Tatyana S.,Lakhvich, Fedor A.
supporting information, (2021/11/30)
Novel O-acylated (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-one oximes were designed as potential HSP90 inhibitors. A series of the compounds was synthesized by oximation of (E)-3-aryl-6,7-dihydrobenzisoxazol-4(5H)-ones followed by O-acylation with acylamid
The evaluation and structure-activity relationships of 2-benzoylaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents
Hsieh, Pei-Wen,Hwang, Tsong-Long,Wu, Chin-Chung,Chiang, Shin-Zan,Wu, Chung-I,Wu, Yang-Chang
, p. 1812 - 1817 (2007/10/03)
Forty-seven 2-benzoylaminobenzoic esters were synthesized and evaluated in anti-platelet aggregation, inhibition of superoxide anion generation, and inhibition of neutrophil elastase release assays. Most 2-benzoylamino-4-chlorobenzoic acid derivatives showed selective inhibitory effects on arachidonic acid (AA)-induced platelet aggregation. Among them, compounds 6b and 7b exhibited more potent inhibitory effects (ca. 200-fold) than aspirin. Additionally, compounds 1a and 5a showed strong inhibitory effects on neutrophil superoxide generation with IC50 values of 0.65 and 0.17 μM, respectively. However, compounds 6d and 6e exhibited dual inhibitory effects on platelet aggregation and neutrophil elastase (NE) release; therefore, these two compounds may be new leads for development as anti-inflammatory and anti-platelet aggregatory agents.
